Drug intelligence / Profile preview

TKP-AII-12

Development stage: Unknown
Lead developer: TheraCea Pharma
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TKP-AII-12 is an 18F-labeled antibody fragment developed by TheraCea Pharma as a diagnostic radiopharmaceutical. It is designed as a Positron Emission Tomography (PET) imaging agent for applications in oncology and neurobiology. The drug utilizes TheraCea's proprietary chemical platform for the site-specific radiofluorination of antibody fragments, which typically offer faster blood clearance and improved tissue penetration compared to full-length antibodies. This allows for high-contrast imaging of specific biological targets associated with cancer and neurological disorders. It is currently in Phase 1 clinical development.

Beyond the preview

Go deeper on TKP-AII-12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TKP-AII-12.

Explore the full profile